5-Fluorouracil (5-FU) has been a cornerstone in cancer treatment for decades, primarily believed to work by damaging DNA and preventing cancer cells from replicating. However, recent research suggests that 5-FU's primary mechanism of action may be through targeting RNA, particularly ribosomal
The trial of handheld translation devices in a network of eight GP surgeries in Southampton has demonstrated impressive results, paving the way for improved communication with 5,850 non-English-speaking patients. This innovative trial spanned several months, from April 2024 to August 2024, and was
The biotech industry is on the brink of a significant transformation, driven by advancements in genetic validation, data-centric investment strategies, and the integration of real-world data (RWD) in clinical trials. By 2025, these innovations are expected to revolutionize cardiovascular research
MilliporeSigma, the Life Science business of Merck KGaA in the U.S. and Canada, has announced a definitive agreement to acquire HUB Organoids Holding B.V. (HUB). This acquisition marks a significant step forward in enhancing their 2D and 3D cell culture portfolio with the innovative technology of
The intricate relationship between our gut microbiota and the risk of developing colon cancer has captivated scientific interest recently, revealing new layers of complexity in how our body's internal systems interact. Researchers at the University of Wisconsin-Madison have discovered that
In the quest to understand the intricate relationships between the gut microbiome and our overall health, researchers from the University of Wisconsin-Madison have uncovered a significant connection between specific microbially-modified bile acids and colorectal cancer risk. This groundbreaking
